Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Chronic inflammation, in turn, enhances the expression of pro-fibrotic factors via the activation of pathways like NF-B, damaging atrial intercellular junction proteins (e.g., Cx40 and Cx43) and affecting electrical signal transmission in the myocardium (Karam et al., 2017)
As research organizations continue evaluating new scientific methodologies, suppliers have expanded digital infrastructure to improve product visibility and documentation
KPV is the strongest anti-inflammatory contributor in the blend, backed by NF-B pathway research and melanocortin-system signaling work
In clinical trials involving over 2,000 patients across various conditions, no clinically significant adverse reactions were attributed to thymosin alpha-1 administration
Athira Pharma (formerly M3 Biotechnology), the WSU spinout founded to commercialize Dihexa-derivative compounds, paid approximately $4 million in a False Claims Act settlement in January 2025 after a whistleblower exposed concealment of the research misconduct from federal grant agencies, and approximately $10 million in a separate class-action settlement to investors
Discontinue use and contact your healthcare provider if you experience any adverse reactions
US$ 23.98
US$ 21.37
US$ 22.48
US$ 23.72
US$ 20.45
US$ 26.13
US$ 23.65
US$ 21.61
US$ 24.84
US$ 21.48
US$ 20.66
US$ 28.11
US$ 23.41
